Company: AEMD
Filing Date: 2025-06-26
Form Type: 10-K
Source: 0001683168-25-004780
Chunk: 870

Company: AETHLON MEDICAL INC
Filing Date: 2025-06-26
Form: 10-K
Item: Item 5
Chunk 870
---
 equal quarterly installments
over one year.

In addition, under the Director
Compensation Policy, at the beginning of each fiscal year, each continuing director eligible to participate will receive a grant of RSUs
with a grant date fair value of $50,000 or, at the discretion of our Board of Directors, options to acquire shares of common stock with
a grant date fair value of $50,000, based on the average of the closing prices of our common stock for the five trading day period ending
on the date of grant and will vest at a rate determined by the Board of Directors in its discretion,
typically in equal quarterly installments over one year.

 70 

Under the Director Compensation
Policy in effect during the fiscal year ended March 31, 2025, in lieu of per meeting fees, eligible directors will receive an annual board
retainer fee of $40,000, as well as the following annual retainer fees: Audit Committee chair - $15,000, Compensation Committee chair
- $15,000, Nominating and Corporate Governance Committee chair - $8,000, Audit Committee member - $7,500 (not applicable to the chair),
Compensation Committee member - $7,500 (not applicable to the chair) and Nominating Committee member - $5,000 (not applicable to the chair).
Additionally, the Chairperson of the Board of Directors will receive an additional annual board retainer fee of $30,000.

ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
AND RELATED STOCKHOLDER MATTERS 

The following table sets forth
information as of March 31, 2025, with respect to the ownership of our common stock, by (i) each person known by us to be the beneficial
owner of more than five percent (5%) of the outstanding shares of each class of our capital stock, (ii) each of our directors and director
nominees, (iii) each of our executive officers, and (iv) all of our named executive officers and directors as a group. As of such date,
we had 2,585,316 shares of our common stock issued and outstanding, after adjustment for the 1-for-8 reverse stock split effective as
of the close of business on June 6, 2025 with an effective trading date of June 9, 2025. We believe that each individual or entity named
has sole investment and voting power with respect to shares